202 related articles for article (PubMed ID: 9389780)
1. Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch.
Hirvonen E; Cacciatore B; Wahlström T; Rita H; Wilén-Rosenqvist G
Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():26-31. PubMed ID: 9389780
[TBL] [Abstract][Full Text] [Related]
2. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy.
Hirvonen E; Lamberg-Allardt C; Lankinen KS; Geurts P; Wilén-Rosenqvist G
Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():19-25. PubMed ID: 9389779
[TBL] [Abstract][Full Text] [Related]
3. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women.
Cameron ST; Critchley HO; Glasier AF; Williams AR; Baird DT
Br J Obstet Gynaecol; 1997 Oct; 104(10):1184-90. PubMed ID: 9332998
[TBL] [Abstract][Full Text] [Related]
4. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
Schram JH; Boerrigter PJ; The TY
Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
[TBL] [Abstract][Full Text] [Related]
5. Impact of percutaneous oestradiol gels in postmenopausal hormone replacement therapy on clinical symptoms and endometrium.
Foidart JM; Béliard A; Hedon B; Ochsenbein E; Bernard AM; Bergeron C; Thomas JL
Br J Obstet Gynaecol; 1997 Mar; 104(3):305-10. PubMed ID: 9091006
[TBL] [Abstract][Full Text] [Related]
6. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
7. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis prevention clinical study program.
Delmas P; Gimona A
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
[TBL] [Abstract][Full Text] [Related]
9. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study.
Hänggi W; Lippuner K; Riesen W; Jaeger P; Birkhäuser MH
Br J Obstet Gynaecol; 1997 Jun; 104(6):708-17. PubMed ID: 9197875
[TBL] [Abstract][Full Text] [Related]
10. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern.
Lübbert H; Nauert C
Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319
[TBL] [Abstract][Full Text] [Related]
11. Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding.
Hirvonen E; Crona N; Wahlström T; Bäckström AC
Climacteric; 2000 Dec; 3(4):262-70. PubMed ID: 11910586
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women.
Hänggi W; Lippuner K; Jaeger P; Birkhäuser MH; Horber FF
Clin Endocrinol (Oxf); 1998 Jun; 48(6):691-9. PubMed ID: 9713556
[TBL] [Abstract][Full Text] [Related]
13. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
van der Mooren MJ; Demacker PN; Thomas CM; Borm GF; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):117-23. PubMed ID: 8157140
[TBL] [Abstract][Full Text] [Related]
14. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users.
Hänggi W; Bersinger N; Altermatt HJ; Birkhäuser MH
Maturitas; 1997 Jun; 27(2):133-43. PubMed ID: 9255748
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
Chiantera V; Sarti CD; Fornaro F; Farzati A; De Franciscis P; Sepe E; Borrelli AL; Colacurci N
Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
[TBL] [Abstract][Full Text] [Related]
16. Combined oral oestradiol valerate-norethisterone treatment over three years in postmenopausal women: correlation between oestrogen levels and bone mineral density sites.
Perry W; Wiseman RA
BJOG; 2000 Nov; 107(11):1401-6. PubMed ID: 11117769
[TBL] [Abstract][Full Text] [Related]
17. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome.
Smith RN; Studd JW; Zamblera D; Holland EF
Br J Obstet Gynaecol; 1995 Jun; 102(6):475-84. PubMed ID: 7632640
[TBL] [Abstract][Full Text] [Related]
18. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
Cieraad D; Conradt C; Jesinger D; Bakowski M
Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
[TBL] [Abstract][Full Text] [Related]
19. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet.
Järvinen A; Nykänen S; Paasiniemi L
Maturitas; 1999 Jun; 32(2):103-13. PubMed ID: 10465378
[TBL] [Abstract][Full Text] [Related]
20. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
